Penile cancer · 6 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Panitumumab monotherapy Variant #01 | — | R 25 254 | 14d | ~1.8 mo | ~10.2 mo | ~4 | ~R 101 017 PFS proxy · indirect | 3 |
Paclitaxel monotherapy Variant #46 | — | R 2 220 | 28d | — | ~8.9 mo | — | — | 4 |
Cisplatin and Fluorouracil (CF) Variant #29 | — | R 1 900 | 21d | ~5.6 mo | ~11.1 mo | ~9 | ~R 17 101 PFS proxy · indirect | 38 |
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug | — | R 743 | 42d | ~3.8 mo | ~12.9 mo | ~3 | ~R 2 230 PFS proxy · indirect | 10 |
PCF N/A - secondary systemic drug | — | R 604 | 21d | — | — | — | — | — |
BMP Variant #01 | — | R 521 | 28d | — | — | — | — | — |
6 of 6 regimens shown